The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall and winter immunization campaigns.

Pfizer and Moderna mRNA vaccines are updated to better match currently circulating COVID strains, while the Novavax adjuvant ...

These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...

Moderna shares fell Thursday morning as the COVID vaccine maker said it plans to cut R&D spending by $1.1 billion over the next three years.

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...